Related Experiment Video

Updated: Mar 3, 2026

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

960

Combination therapy for the treatment of pulmonary mold infections

Matthew William McCarthy1, Vidmantas Petraitis2, Thomas J Walsh3

  • 1a Hospital Medicine , Joan and Sanford I Weill Medical College of Cornell University , New York , NY , USA.

Expert Review of Respiratory Medicine
|May 4, 2017
PubMed
Abstract

Insights

Antifungal combination therapy shows promise for treating pulmonary mold infections, a challenging fungal disease. Recent advances address previous limitations, potentially improving clinical outcomes for invasive mycoses.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Pulmonary mold infections are caused by common environmental fungi like Aspergillus and Mucormycetes.
  • These infections pose significant diagnostic and therapeutic challenges.
  • Antifungal combination therapy is a developing strategy for invasive mycoses.

Purpose of the Study:

  • To review current knowledge on antifungal combination therapy for pulmonary mold infections.
  • To discuss the potential impact of this approach on clinical practice.
  • To highlight novel combinations and challenges in antifungal drug development.

Main Methods:

  • Literature review of antifungal combination therapy in pulmonary mold infections.
  • Analysis of challenges in interpreting in vitro data and predicting clinical success.
  • Exploration of recent advances mitigating these challenges.

Main Results:

  • Historically, combination therapy faced limitations due to variable interpretation criteria and drug properties.
  • Recent advancements are improving the predictability and efficacy of combination therapies.
  • Novel combinations and new antifungal agent development are areas of active research.

Conclusions:

  • Antifungal combination therapy offers a promising avenue for treating pulmonary mold infections.
  • Overcoming historical challenges through recent advances can enhance clinical outcomes.
  • Continued research into novel combinations and antifungal agents is crucial for managing invasive mycoses.
Keywords:
Aspergillosisechinocandinisavuconazolemucormycosispolyenetriazole

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

1.2K
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

12.1K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
694
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
588
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
916
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
958
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.3K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K